Form 4: Kymera Therapeutics CEO Nello Mainolfi Reports Stock Option Exercise and Share Disposal
SEC Form 4 Filing
CEO Nello Mainolfi exercised stock options and disposed of shares of Kymera Therapeutics, Inc. on July 1, 2024.
Summary
- On July 1, 2024, Nello Mainolfi, CEO of Kymera Therapeutics, exercised stock options to acquire 18,773 shares of common stock at a price of $5.33 per share.
- Simultaneously, Mainolfi disposed of 18,773 shares.
- Following these transactions, Mainolfi directly owns 649,959 shares of common stock and holds options for 288,456 shares.
- The stock options vest in 48 equal monthly installments from May 14, 2020, contingent upon continued employment.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| May 14, 2020 | Vesting commencement date for the stock options. |
| May 13, 2030 | Expiration date of the stock options. |
| July 1, 2024 | Date of stock option exercise and share disposal. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.